- Home
- CASI vs FAAS Comparison
CASI vs FAAS Comparison
Compare CASI & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- FAAS
- Stock Information
- Founded
- CASI 1991
- FAAS 2021
- Country
- CASI China
- FAAS Indonesia
- Employees
- CASI N/A
- FAAS N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- FAAS
- Sector
- CASI Health Care
- FAAS
- Exchange
- CASI Nasdaq
- FAAS NYSE
- Market Cap
- CASI 33.4M
- FAAS 34.6M
- IPO Year
- CASI 1996
- FAAS N/A
- Fundamental
- Price
- CASI $1.94
- FAAS $0.20
- Analyst Decision
- CASI Strong Buy
- FAAS
- Analyst Count
- CASI 1
- FAAS 0
- Target Price
- CASI $4.00
- FAAS N/A
- AVG Volume (30 Days)
- CASI 13.6K
- FAAS 662.1K
- Earning Date
- CASI 05-13-2025
- FAAS 01-01-0001
- Dividend Yield
- CASI N/A
- FAAS N/A
- EPS Growth
- CASI N/A
- FAAS N/A
- EPS
- CASI N/A
- FAAS N/A
- Revenue
- CASI $28,537,000.00
- FAAS $57,730,593.00
- Revenue This Year
- CASI $66.12
- FAAS N/A
- Revenue Next Year
- CASI $51.37
- FAAS N/A
- P/E Ratio
- CASI N/A
- FAAS N/A
- Revenue Growth
- CASI N/A
- FAAS 38.16
- 52 Week Low
- CASI $1.88
- FAAS $0.20
- 52 Week High
- CASI $7.67
- FAAS $10.63
- Technical
- Relative Strength Index (RSI)
- CASI 41.12
- FAAS 31.51
- Support Level
- CASI $1.91
- FAAS $0.21
- Resistance Level
- CASI $2.14
- FAAS $0.24
- Average True Range (ATR)
- CASI 0.20
- FAAS 0.05
- MACD
- CASI -0.01
- FAAS 0.00
- Stochastic Oscillator
- CASI 11.11
- FAAS 6.94
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.